Aethlon Medical

Aethlon Medical has amended the employment agreements of CEO James B. Frakes and CFO/CMO Dr. Steven P. LaRosa so that severance payments and health insurance contributions in the event of a change of control will be paid as lump sums rather than in installments. The company stresses that the amounts and eligibility conditions for the payments remain unchanged; lump sums become payable on the first regular payroll date after the employee is placed on administrative leave and are final once paid. AEMD shares have lost about 96% over the past year and are trading near their 52‑week low; the company also reported an adjusted Q1 2027 loss of $4.02 per share, missing estimates. Aethlon highlighted progress in a phase‑1 study in solid tumors in Australia, and H.C. Wainwright rates the stock as “Neutral” with a $1.50 price target. » Więcej na de.investing.com

Aethlon Medical reported preliminary efficacy signals for its blood-filtration device Hemopurifier from an Australian oncology study at the Emerging Growth Conference, observing a possible dose–response pattern with more consistent EV reductions after multiple treatments. The company said that across roughly 150 treatments there were no device-related serious adverse events or dose-limiting toxicities. Cash on hand was about $4.9 million as of June 30, plus roughly $4 million in gross proceeds, which the company says should fund operations for at least 12 months. Aethlon plans to complete the final cohort and follow-up by the end of 2026, intends to engage with U.S. and Australian regulators, and is exploring uses such as long COVID; however, broader studies will require additional funding and regulatory feedback. » Więcej na de.investing.com

Aethlon Medical released results for the quarter ended June 30, 2026, reporting a loss of $4.02 per share. In the same quarter a year earlier, the loss was $42,500 per share. » Więcej na finanzen.net